Risk factors for COVID-19 associated pulmonary aspergillosis and outcomes in patients with acute respiratory failure in a respiratory sub-intensive care unit
Background COVID-19-associated pulmonary aspergillosis (CAPA) is burdened by high mortality. Data are lacking about non-ICU patients. Aims of this study were to: (i) assess the incidence and prevalence of CAPA in a respiratory sub-intensive care unit, (ii) evaluate its risk factors and (iii) impact on in-hospital mortality. Secondary aims were to: (i) assess factors associated to mortality, and (ii) evaluate significant features in hematological patients. Materials and methods This was a single-center, retrospective study of COVID-19 patients with acute respiratory failure. A cohort of CAPA patients was compared to a non-CAPA cohort. Among patients with CAPA, a cohort of hematological patients was further compared to another of non-hematological patients. Results Three hundred fifty patients were included in the study. Median P/F ratio at the admission to sub-intensive unit was 225 mmHg (IQR 155–314). 55 (15.7%) developed CAPA (incidence of 5.5%). Eighteen had probable CAPA (37.3%), 37 (67.3%) possible CAPA and none proven CAPA. Diagnosis of CAPA occurred at a median of 17 days (IQR 12–31) from SARS-CoV-2 infection. Independent risk factors for CAPA were hematological malignancy [OR 1.74 (95%CI 0.75–4.37), p = 0.0003], lymphocytopenia [OR 2.29 (95%CI 1.12–4.86), p = 0.02], and COPD [OR 2.74 (95%CI 1.19–5.08), p = 0.014]. Mortality rate was higher in CAPA cohort (61.8% vs 22.7%, p < 0.0001). CAPA resulted an independent risk factor for in-hospital mortality [OR 2.92 (95%CI 1.47–5.89), p = 0.0024]. Among CAPA patients, age > 65 years resulted a predictor of mortality [OR 5.09 (95% CI 1.20–26.92), p = 0.035]. No differences were observed in hematological cohort. Conclusion CAPA is a life-threatening condition with high mortality rates. It should be promptly suspected, especially in case of hematological malignancy, COPD and lymphocytopenia..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
---|---|
Enthalten in: |
BMC infectious diseases - 24(2024), 1 vom: 11. Apr. |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Iacovelli, Alessandra [VerfasserIn] |
---|
Links: |
Volltext [kostenfrei] |
---|
BKL: | |
---|---|
Themen: |
CAPA |
Anmerkungen: |
© The Author(s) 2024 |
---|
doi: |
10.1186/s12879-024-09283-3 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
SPR055491030 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | SPR055491030 | ||
003 | DE-627 | ||
005 | 20240412064639.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240412s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1186/s12879-024-09283-3 |2 doi | |
035 | |a (DE-627)SPR055491030 | ||
035 | |a (SPR)s12879-024-09283-3-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 610 |q VZ |
084 | |a 44.00 |2 bkl | ||
100 | 1 | |a Iacovelli, Alessandra |e verfasserin |4 aut | |
245 | 1 | 0 | |a Risk factors for COVID-19 associated pulmonary aspergillosis and outcomes in patients with acute respiratory failure in a respiratory sub-intensive care unit |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a © The Author(s) 2024 | ||
520 | |a Background COVID-19-associated pulmonary aspergillosis (CAPA) is burdened by high mortality. Data are lacking about non-ICU patients. Aims of this study were to: (i) assess the incidence and prevalence of CAPA in a respiratory sub-intensive care unit, (ii) evaluate its risk factors and (iii) impact on in-hospital mortality. Secondary aims were to: (i) assess factors associated to mortality, and (ii) evaluate significant features in hematological patients. Materials and methods This was a single-center, retrospective study of COVID-19 patients with acute respiratory failure. A cohort of CAPA patients was compared to a non-CAPA cohort. Among patients with CAPA, a cohort of hematological patients was further compared to another of non-hematological patients. Results Three hundred fifty patients were included in the study. Median P/F ratio at the admission to sub-intensive unit was 225 mmHg (IQR 155–314). 55 (15.7%) developed CAPA (incidence of 5.5%). Eighteen had probable CAPA (37.3%), 37 (67.3%) possible CAPA and none proven CAPA. Diagnosis of CAPA occurred at a median of 17 days (IQR 12–31) from SARS-CoV-2 infection. Independent risk factors for CAPA were hematological malignancy [OR 1.74 (95%CI 0.75–4.37), p = 0.0003], lymphocytopenia [OR 2.29 (95%CI 1.12–4.86), p = 0.02], and COPD [OR 2.74 (95%CI 1.19–5.08), p = 0.014]. Mortality rate was higher in CAPA cohort (61.8% vs 22.7%, p < 0.0001). CAPA resulted an independent risk factor for in-hospital mortality [OR 2.92 (95%CI 1.47–5.89), p = 0.0024]. Among CAPA patients, age > 65 years resulted a predictor of mortality [OR 5.09 (95% CI 1.20–26.92), p = 0.035]. No differences were observed in hematological cohort. Conclusion CAPA is a life-threatening condition with high mortality rates. It should be promptly suspected, especially in case of hematological malignancy, COPD and lymphocytopenia. | ||
650 | 4 | |a CAPA |7 (dpeaa)DE-He213 | |
650 | 4 | |a COVID-19 |7 (dpeaa)DE-He213 | |
650 | 4 | |a Respiratory failure |7 (dpeaa)DE-He213 | |
650 | 4 | |a Sub-intensive care unit |7 (dpeaa)DE-He213 | |
650 | 4 | |a Lymphocytopenia |7 (dpeaa)DE-He213 | |
700 | 1 | |a Oliva, Alessandra |e verfasserin |4 aut | |
700 | 1 | |a Mirabelli, Flavio Marco |e verfasserin |4 aut | |
700 | 1 | |a Giannone, Silvia |e verfasserin |4 aut | |
700 | 1 | |a Laguardia, Marianna |e verfasserin |4 aut | |
700 | 1 | |a Morviducci, Matteo |e verfasserin |4 aut | |
700 | 1 | |a Nicolardi, Maria Luisa |e verfasserin |4 aut | |
700 | 1 | |a Repaci, Emma |e verfasserin |4 aut | |
700 | 1 | |a Sanzari, Maria Teresa |e verfasserin |4 aut | |
700 | 1 | |a Leanza, Cristiana |e verfasserin |4 aut | |
700 | 1 | |a Raponi, Giammarco |e verfasserin |4 aut | |
700 | 1 | |a Mastroianni, Claudio |e verfasserin |4 aut | |
700 | 1 | |a Palange, Paolo |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t BMC infectious diseases |d BioMed Central, 2001 |g 24(2024), 1 vom: 11. Apr. |w (DE-627)SPR027459152 |w (DE-600)2041550-3 |x 1471-2334 |7 nnns |
773 | 1 | 8 | |g volume:24 |g year:2024 |g number:1 |g day:11 |g month:04 |
856 | 4 | 0 | |u https://dx.doi.org/10.1186/s12879-024-09283-3 |m X:VERLAG |x 0 |z kostenfrei |3 Volltext |
912 | |a GBV_SPRINGER | ||
912 | |a SSG-OLC-PHA | ||
936 | b | k | |a 44.00 |q VZ |
951 | |a AR | ||
952 | |d 24 |j 2024 |e 1 |b 11 |c 04 |